Feel free to join and "follow all" in our starter pack ☺️: go.bsky.app/4cMqxsU
11.02.2026 19:50
👍 5
🔁 2
💬 0
📌 0
Feel free to join and "follow all" in our starter pack ☺️: go.bsky.app/4cMqxsU
🥳 Congratulations, David Tornai et al. from Maria Papp's team at the University of Debrecen! The paper has been viewed more than 625 times since its publication in Dec 2025 & is currently amongst the top-downloaded articles!
#SerumVillin #GutBarrier #ACLF
📰 onlinelibrary.wiley.com/doi/10.1111/...
🧪 Priority ahead: A strong push to reach 240 patients in the #ALBTRIAL - crucial for robust clinical validation and real patient impact
🏆 And congratulations to Aleksander Krag on the #HagedornPrize for groundbreaking work in early detection of #LiverDisease - an inspiration to the whole consortium
👏 Huge thanks to the SC + all team members for open discussions and constructive feedback. Now it’s time to roll up our sleeves & push hard toward the project finish line (Sept 2026). Delivering high-quality outputs to our funding agency (EU) is ambitious but absolutely achievable. We can do it! 🏃♀️🏃♂️
Across all WPs, we saw impressive progress - from clinical and genetic characterisation to #microbiome, multi #omics, experimental validation & systems #modelling. Major advances in #proteomics, #metabolomics, #biomarkers & prediction models - highlight the power of our multidisciplinary team. 🔬
🩺🧪🦠 Thank you, team MICROB-PREDICT, for a strong and successful 15th #SteeringCommittee Meeting. Two intense days with excellent science and great discussions - held in a time of shared grief as we remember #PeerBork from #EMBL 🖤, our esteemed colleague and mentor🕯️. We move forward with momentum! 💪
Prof. Peer Bork, EMBL Interim Director General, died on 16 January 2026. A remarkable scientist and leader, he played a pivotal role in MICROB-PREDICT, inspiring colleagues & mentees alike - leaving a lasting scientific legacy. Our heartfelt condolences to his family. Thank you for everything, Peer!
Save the date! We look forward to our upcoming steering committee (SC) meeting from 26-27 January 2026. We’ll hear about the results in all work packages and align the consortium's efforts for the next steps in our cross-disciplinary collaboration! @easlnews.bsky.social @horizoneu.bsky.social
Prices:
€60 €
45 - Students, unemployed, pensioners, over 65s, Friends of the CCCB
Registrations:
Course offered in both in-person and online formats. Register here .
www.cccb.org/es/actividad...
In 2026, the Universitat de Barcelona will collaborate again with the Centre de Cultura Contemporània de Barcelona (CCCB) to talk about "bodies, data, and the market - Reflections from bioethics" - don't miss it!
📅 26 February and 5, 12, 19 and 26 March 2026
🫖 Snuggle in with a cup of tea and a blanket over the holidays to read this year's MICROB-PREDICT publications - Wishing everyone relaxing winter holidays and a wonderful start into the New Year! ❄️
📖 microb-predict.eu/for-scientis...
@medblab.bsky.social
@easlnews.bsky.social
@ec.europa.eu
As the year draws to a close, we are wrapping up 2025 with gratitude, momentum, and a spirit of community at concentris. ✨
💡Curious about what’s next in 2026, and how these developments could support your work?
Read our latest #newsletter:
🔗 mailchi.mp/concentris/n...
👉 In this video, Dávid Tornai (MD, PhD) from Maria Papp's group at the University of Debrecen in Hungary presents the consortium's research on serum #villin-1, a tell-tale sign of #GutBarrier failure in cirrhotic patients with acute #decompensation via a graphical abstract.
📽️ youtu.be/URerer6AxxY
👏 New study from Dávid Tornai and colleagues 🎉: Serum #Villin1 is a promising non-invasive marker of #GutBarrier damage in #cirrhosis and #ACLF.
It rises with severity, predicts 90-day mortality, links to #inflammation, and has been validated in an independent cohort!
📜 doi.org/10.1111/apt....
📽️ Now online 🎧: lnkd.in/dJuMmsc4
Watch or listen to the newest EASL Studio Episode on “Rifaximin for Hepatic Encephalopathy: Balancing Benefits and Risks in the Era of Antimicrobial Resistance” from Wednesday, 26 Nov 2026.
#rifaximin #HepaticEncephalopathy #AntimicrobialResistance #cirrhosis #ACLF
The session will also be available to watch on demand on EASL Campus from Thursday, 27 November
👉 easlcampus.eu/easl-studio/...
Within MICROB-PREDICT, WP6 is uncovering the mechanisms by which rifaximin & albumin interact with the microbiome and the gut–liver axis, using cellular + rodent models.
On Wednesday, 26 Nov, at 6 pm CET, EASL Studio hosts a new episode titled “Rifaximin for Hepatic Encephalopathy: Balancing Benefits and Risks in the Era of Antimicrobial Resistance”
The episode will be broadcast live on EASL.eu and can be accessed here:
📹 easl.eu/easl-studio-...
Don't miss it ☺️
🎉 Our new #mirobiome paper in #JHEP is out! We found distinct gut #virome shifts in #ACLF - from virulent to temperate #phages - with Lactococcus A + Enterococcus B phages linked to infections & higher 90-day mortality
👉 Read more: www.sciencedirect.com/science/arti...
📽️Video: youtu.be/0YF6qToBQUM
🌍 The MICROB-PREDICT team met in Münster, Germany from 1–2 October for its 14th Steering Committee Meeting!
👉 Team leaders discussed results from 20 new papers about late-stage #LiverDisease #cirrhosis #biomarkers and IPR topics as the project nears its final phase.
The finish line is in sight!
🔬 Read the original publication by Boglarka Balogh, David Tornai, Aniko Csillag et al. (2025) on behalf of the MICROB-PREDICT consortium and the PREDICT study group of the EASL-CLIF consortium: onlinelibrary.wiley.com/doi/10.1111/...
🚨 New #LiverFailure insights 🚨
In patients with #cirrhosis + acute #decompensation, secretory #IgA strongly correlates with #gut-barrier failure and is a powerful predictor of 90-day mortality in acute-on-chronic #LiverFailure #ACLF
👉 Watch on YouTube: youtu.be/KapUqG7AFFk
#Biomarkers #GutBarrier
Both groups (placebo vs. #albumin treatment) are monitored closely regarding their liver disease & overall health. We thank the dedicated teams at all sites across Europe for their hard work in achieving this milestone. We look forward to continuing this progress toward completing the ALB-TRIAL! 💪
The ALB-TRIAL is a double-blinded, placebo-controlled clinical trial to see if a new biomarker can be used to predict which patients with #cirrhosis + #ascites benefit most from long-term human #albumin infusion. Moving towards personalised treatment, less complications & lower risk of death. 🔬⚕️🩺
👏 ALB-TRIAL hits 50% enrollment 🎉
Half of the planned 240 patients have now been recruited across 14 centres in 7 countries - great progress for the MICROB-PREDICT project!
Huge thanks to all site teams - Onward to full enrollment & better treatment for #cirrhosis patients with #ascites!
#albumin
Join this exciting event!
Don't miss our #OpenInnovation event, uniting experts in #DrugDevelopment, #bioinformatics, and #hepatology. Connect with researchers, industry professionals, and investors to share insights & explore collaboration opportunities!
🚀 Register now: inevent.uk/en/Crowdheli...
🧪 SAT-209 – #EASL2025
MNK6106 vs. rifaximin to treat #HepaticEncephalopathy - new Phase 2a data from Prof. @rajivjalan.bsky.social (UCL) explores safety, PK & ammonia-lowering potential. HE treatment innovation in motion! #Cirrhosis
🧠 SAT-210 – #EASL2025
New tool alert!
The #mHEST scale brings clarity to grading hepatic #encephalopathy in trials & clinics. A big step for #cirrhosis care. Kudos to Prof. @rajivjalan.bsky.social & his team!
#LiverHealth #HE #ClinicalResearch
🔬 Improving the prognostic performance of the #MELD score is a challenge that Nikolaj Torp (Odense University Hospital) took on, comparing the original score with MELD 3.0 in 777 patients with an acute #decompensation of #cirrhosis
#POSTER SAT-196-YI 👏
📅 Presented at #EASLCongress | #EASL2025
✨ #PosterTour today at #EASLCongress 2025:
All our 3 Horizon2020 #LiverResearch projects in 1 session!
Topic: #Cirrhosis & #PortalHypertension
Chair: Maria Papp
💡 Big moments:
#AMMON-OHE model for post-#TIPS #encephalopathy (Rajiv Jalan)
#Terlipressin response in AKI-HRS w/ CKD (Frank Uschner)
@easlnews.bsky.social
